MedTrace Logo

Evaluation of [18F]APN-1607 as a PET Biomarker

NCT05005819 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-02-20

No results posted yet for this study

Summary

The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.

Conditions

Interventions

DRUG

[18F] APN-1607

Subjects will undergo PET imaging using \[18F\]APN-1607.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • David Russell, M.D., Ph.D. · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2024-01-09
Completion
2024-01-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005819 on ClinicalTrials.gov